- Home
- GLSI vs OBIO Comparison
GLSI vs OBIO Comparison
Compare GLSI & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- OBIO
- Stock Information
- Founded
- GLSI 2006
- OBIO 2017
- Country
- GLSI United States
- OBIO United States
- Employees
- GLSI N/A
- OBIO N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- GLSI Health Care
- OBIO Health Care
- Exchange
- GLSI Nasdaq
- OBIO Nasdaq
- Market Cap
- GLSI 133.4M
- OBIO 151.3M
- IPO Year
- GLSI 2020
- OBIO N/A
- Fundamental
- Price
- GLSI $9.66
- OBIO $3.31
- Analyst Decision
- GLSI Strong Buy
- OBIO Strong Buy
- Analyst Count
- GLSI 1
- OBIO 5
- Target Price
- GLSI $39.00
- OBIO $14.20
- AVG Volume (30 Days)
- GLSI 36.1K
- OBIO 193.7K
- Earning Date
- GLSI 05-20-2025
- OBIO 05-12-2025
- Dividend Yield
- GLSI N/A
- OBIO N/A
- EPS Growth
- GLSI N/A
- OBIO N/A
- EPS
- GLSI N/A
- OBIO N/A
- Revenue
- GLSI N/A
- OBIO $2,886,000.00
- Revenue This Year
- GLSI N/A
- OBIO $29.80
- Revenue Next Year
- GLSI N/A
- OBIO N/A
- P/E Ratio
- GLSI N/A
- OBIO N/A
- Revenue Growth
- GLSI N/A
- OBIO 30.23
- 52 Week Low
- GLSI $8.06
- OBIO $2.37
- 52 Week High
- GLSI $18.75
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- GLSI 48.32
- OBIO 59.49
- Support Level
- GLSI $9.25
- OBIO $3.05
- Resistance Level
- GLSI $10.00
- OBIO $3.49
- Average True Range (ATR)
- GLSI 0.48
- OBIO 0.21
- MACD
- GLSI -0.02
- OBIO 0.07
- Stochastic Oscillator
- GLSI 30.10
- OBIO 79.66
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.